Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis

Brad H Rovin; Isabelle M Ayoub; Tak Mao Chan; Zhi-Hong Liu; Juan M Mejía-Vilet; Ethan M Balk; Craig E Gordon; Gaelen Adam; Marcello A Tonelli; Michael Cheung; Amy Earley; Jürgen Floege

doi:10.1016/j.kint.2023.09.001

Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis

Kidney Int. 2024 Jan;105(1):31-34. doi: 10.1016/j.kint.2023.09.001.

Authors

Affiliations

¹ Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, Ohio, USA. Electronic address: Brad.Rovin@osumc.edu.
² Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, Ohio, USA.
³ Division of Nephrology, Department of Medicine, University of Hong Kong, Hong Kong, China.
⁴ National Clinical Research Center of Kidney Diseases, Nanjing University School of Medicine, Nanjing, China.
⁵ Department of Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Medicas y Nutricion, Salvador Zubiran, Mexico City, Mexico.
⁶ Center for Evidence Synthesis in Health, Brown University School of Public Health, Providence, Rhode Island, USA.
⁷ Division of Nephrology, Tufts Medical Center, Boston, Massachusetts, USA.
⁸ Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
⁹ KDIGO, Brussels, Belgium.
¹⁰ Division of Nephrology, University Hospital, Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen, Aachen, Germany.

PMID: 38182299
DOI: 10.1016/j.kint.2023.09.001

Abstract

The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Glomerular Diseases was published in 2021. Since then, the pace of drug development for glomerular diseases has accelerated, due in large part to rapidly accumulating insights into disease pathogenesis from genetic and molecular studies of afflicted patients. To keep the Glomerular Diseases Guideline as current as possible, KDIGO made a commitment to the nephrology community to provide periodic updates, based on new developments for each disease. After the 2021 guideline was published, two novel drugs received regulatory approval for the management of lupus nephritis, leading to the first KDIGO guideline update. Herein, an executive summary of the most important guideline changes from the Lupus Nephritis chapter is provided as a quick reference.

Keywords: KDIGO; glomerular diseases; glomerulonephritis; guideline; lupus nephritis; systematic review.

Publication types

Practice Guideline
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Drug Development
Humans
Kidney
Lupus Nephritis* / diagnosis
Lupus Nephritis* / drug therapy
Nephrology*